A Phase 1 interventional study of AZD4954 and Placebo in Healthy Participants and Dyslipidemia, sponsored by AstraZeneca. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Dyslipidemias by AstraZeneca — 1 open to participants now, 3 under way, 1 of them phase 3. Dyslipidemias · AstraZeneca.
Among the 57 studies in Dyslipidemias by AstraZeneca, this one is the 18th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 16 in phase 1, and was the 51st registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →1 of the 57 studies in Dyslipidemias by AstraZeneca is open now, in 1 country.
By country, each count listing its studies:
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 6 · Phase 3 15 · Phase 4 1
First in 2002; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 171 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 119 across the 37 interventional studies, 2,075 across the 20 observational. Of the 52 that completed or were terminated, 11 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
2 of the studies in Dyslipidemias by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834932Phase 3AstraZenecaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | 2027-02-22 |
| NCT06980428AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia | 2027-04-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 57 studies in Dyslipidemias by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp[a]) levels and participants with dyslipidemia.
This is a first time in human, placebo-controlled, single and multiple ascending dose (SAD and MAD) study in healthy male and female participants (Part A) or healthy participants with elevated Lp(a) levels (≥ 30 mg/dL, [62 nmol/L]) and participants with dyslipidemia with elevated Lp(a) levels (≥ 70 mg/dL, [150 nmol/L]) and low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL and \< 190 mg/dL (Part B).
The study consists of 2 parts: Part A (SAD) and Part B (MAD).
Part A of the study will consist of Part A1 and Part A2, comprising:
Part B has 3 types of MAD cohorts - global cohorts with healthy participants, global cohort with participants with dyslipidemia, and a Japanese cohort. The global MAD cohorts (healthy participants) and Japanese MAD cohort will comprise:
The global MAD cohort (participants with dyslipidemia) will comprise:
The criteria were revised on the registry on Nov 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Parts:
Parts A and B (Healthy Participants):
For Japanese and Chinese participants (Parts A and B):
A Chinese participant is defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.
Part B (Healthy Participants):
Part B (Participants with Dyslipidemia):
Exclusion Criteria:
All Parts:
Parts A and B (Healthy Participants):
Part B (Participants with Dyslipidemia):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of AZD4954 (Dose 1) or matching placebo on Day 1.
Drug: AZD4954 · Drug: Placebo
Participants will receive a single dose of AZD4954 (Dose 2) or matching placebo on Day 1.
Drug: AZD4954 · Drug: Placebo
Participants will receive a single dose of AZD4954 (Dose 3) or matching placebo on Day 1.
Drug: AZD4954 · Drug: Placebo
Participants will receive a single dose of AZD4954 (Dose 4) or matching placebo on Day 1.
Drug: AZD4954 · Drug: Placebo
Participants will receive a single dose of AZD4954 (Dose 5) or matching placebo on Day 1.
Drug: AZD4954 · Drug: Placebo
This additional cohort may be added depending on the findings.
Drug: AZD4954 · Drug: Placebo
Japanese participants will receive a single dose of AZD4954 (Dose 2) or matching placebo on Day 1.
Drug: AZD4954 · Drug: Placebo
Japanese participants will receive a single dose of AZD4954 (Dose 3) or matching placebo on Day 1.
Drug: AZD4954 · Drug: Placebo
This additional cohort may be added depending on the findings.
Drug: AZD4954 · Drug: Placebo
Chinese participants will receive a single dose of AZD4954 (Dose 5) or matching placebo at the highest dose level on Day 1.
Drug: AZD4954 · Drug: Placebo
Participants will receive a single dose of AZD4954 (Dose 2) or matching placebo with a high-calorie, high-fat breakfast on Day 1.
Drug: AZD4954 · Drug: Placebo
Participants will receive a single dose of AZD4954 (Dose 3) or matching placebo with a high-calorie, high-fat breakfast on Day 1.
Drug: AZD4954 · Drug: Placebo
Participants will receive multiple doses of AZD4954 (Dose 1) or matching placebo for 21 days.
Drug: AZD4954 · Drug: Placebo
Participants will receive multiple doses of AZD4954 (Dose 2) or matching placebo for 21 days.
Drug: AZD4954 · Drug: Placebo
Participants will receive multiple doses of AZD4954 (Dose 3) or matching placebo for 21 days.
Drug: AZD4954 · Drug: Placebo
Participants will receive multiple doses of AZD4954 or matching placebo for 21 days. This additional cohort may be added depending on the findings.
Drug: AZD4954 · Drug: Placebo
Participants will receive multiple doses of AZD4954 or matching placebo for 21 days. This additional cohort may be added depending on the findings.
Drug: AZD4954 · Drug: Placebo
Participants will receive multiple doses of AZD4954 or matching placebo for 21 days. This additional cohort may be added depending on the findings.
Drug: AZD4954 · Drug: Placebo
Japanese participants will receive multiple doses of AZD4954 (Dose 3) or matching placebo for 21 days.
Drug: AZD4954 · Drug: Placebo
Participants with dyslipidemia will receive multiple doses of AZD4954 (Dose 6) or matching placebo for 21 days.
Drug: AZD4954 · Drug: Placebo
AZD4954 will be administered orally.
Placebo will be administered orally.
Part A: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
To assess the safety and tolerability of AZD4954 following oral administration of SAD (Part A).
Time frame: From Screening (Day -28 to Day -2) to Follow-up visit (Up to Day 29±2 days)
Part B: Number of participants with AEs and SAEs
To assess the safety and tolerability of AZD4954 following oral administration of MAD (Part B).
Time frame: From Screening (Day -28 to Day -2) to Follow-up visit (Up to Day 49±2 days)
Part A: Area under concentration-time curve from time 0 to infinity (AUCinf)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Up to Day 29±2 days
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Part B: Area under concentration-time curve in the dosing interval (AUCtau)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Up to Day 49±2 days
Dose normalized AUClast (AUClast/D)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Dose normalized AUCinf (AUCinf/D)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Part B: Dose normalized AUCtau (AUCtau/D)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Up to Day 49±2 days
Apparent total body clearance (CL/F)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Maximum observed drug concentration (Cmax)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Dose normalized Cmax (Cmax/D)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Terminal elimination half-life (t1/2λz)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Time of last quantifiable concentration (tlast)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Time to reach maximum observed concentration (tmax)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Apparent volume of distribution based on the terminal phase (Vz/F)
To characterize the single dose and/or steady state pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 29±2 days; Part B: Up to Day 49±2 days
Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae[t1-t2])
To characterize the single dose and/or steady state urine pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 15; Part B: Up to Day 22
Cumulative amount of unchanged drug excreted into urine (Aeinf)
To characterize the single dose and/or steady state urine pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 15; Part B: Up to Day 22
Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe[t1-t2])
To characterize the single dose and/or steady state urine pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 15; Part B: Up to Day 22
Renal clearance (CLR)
To characterize the single dose and/or steady state urine pharmacokinetics of AZD4954 following oral administration of AZD4954.
Time frame: Part A: Up to Day 15; Part B: Up to Day 22
Part B: Absolute change from baseline in serum Lp(a)
To evaluate the pharmacodynamics of AZD4954 by assessment of Lp(a) levels following repeated oral dosing.
Time frame: Up to Day 49±2 days
Part B: Relative change from baseline in serum Lp(a)
To evaluate the pharmacodynamics of AZD4954 by assessment of Lp(a) levels following repeated oral dosing.
Time frame: Up to Day 49±2 days
Part B: Absolute change from baseline in Lp(a) intact assay
To evaluate the pharmacodynamics of AZD4954 by assessment of Lp(a) levels following repeated oral dosing.
Time frame: Up to Day 49±2 days
Part B: Relative change from baseline in Lp(a) intact assay
To evaluate the pharmacodynamics of AZD4954 by assessment of Lp(a) levels following repeated oral dosing.
Time frame: Up to Day 49±2 days
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.
Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 22 months is above that.
Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD4954